Latest Regulatory Engagement News

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

Trigg Minerals has solidified its ownership of the Wild Cattle Creek antimony deposit with NSW government approval and confirmed high-grade antimony and tungsten mineralisation beneath the site. The company also expanded its New South Wales footprint through strategic acquisitions of historic gold and antimony projects.

Nagambie Resources reported significant new antimony-gold intersections at its Nagambie Mine and joined a US Department of Defence consortium, positioning itself amid soaring antimony prices and strategic demand. The company also advanced funding arrangements and plans a resource update in the June quarter.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Novatti Group Limited has achieved a key turnaround milestone by reporting positive cash EBITDA of $100k in Q3 FY25, alongside record quarterly revenue of $13.4 million and improved margins in its core Payments AU/NZ business.

Gibb River Diamonds has secured a key mining lease at its Edjudina Gold Project and lodged a mining proposal to kickstart operations at the Neta Prospect, alongside announcing a new JORC Inferred Resource for historic leach pads.

Island Pharmaceuticals has completed dosing in the Phase 2b cohort of its dengue fever trial, with pharmacokinetic targets met and top-line results expected next month. The company also strengthened its balance sheet by raising $1.94 million through option exercises.

Immutep Limited has dosed the first patient in its pivotal Phase III lung cancer trial and completed enrolments in multiple studies, supported by a robust cash position expected to fund operations through 2026.

29Metals Limited reports solid operational progress at Golden Grove with cost improvements and project development, while Capricorn Copper remains suspended focusing on water management and regulatory compliance. The company completes senior debt refinancing, maintaining strong liquidity and guidance.

Lithium Universe Limited’s Definitive Feasibility Study confirms the economic viability of its Bécancour Lithium Refinery, projecting robust returns even amid subdued lithium prices. The project aims to produce 18,270 tonnes per year of battery-grade lithium carbonate, leveraging proven Jiangsu technology and a counter-cyclical development strategy.

Island Pharmaceuticals has successfully completed patient dosing in the Phase 2b therapeutic arm of its PROTECT clinical trial for ISLA-101, targeting dengue fever treatment. High-level results are expected within two months, potentially advancing a significant antiviral candidate.

Alterity Therapeutics has raised A$40 million through a two-tranche placement to advance its lead compound ATH434 for neurodegenerative diseases, including Multiple System Atrophy and Parkinson's disease.